235 related articles for article (PubMed ID: 23214161)
1. [Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression].
Krawczyk K; Rybakowski J
Psychiatr Pol; 2012; 46(4):585-98. PubMed ID: 23214161
[TBL] [Abstract][Full Text] [Related]
2. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
[TBL] [Abstract][Full Text] [Related]
3. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
[TBL] [Abstract][Full Text] [Related]
4. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
Schindler F; Anghelescu IG
Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
[TBL] [Abstract][Full Text] [Related]
5. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
Alevizos B; Alevizos E; Leonardou A; Zervas I
Psychiatriki; 2012; 23(2):143-8. PubMed ID: 22796912
[TBL] [Abstract][Full Text] [Related]
6. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
[TBL] [Abstract][Full Text] [Related]
7. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
8. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
[TBL] [Abstract][Full Text] [Related]
9. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
Amsterdam JD; Shults J
J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
[TBL] [Abstract][Full Text] [Related]
10. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
11. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
[TBL] [Abstract][Full Text] [Related]
12. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
[TBL] [Abstract][Full Text] [Related]
13. Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression.
Amsterdam JD; Lorenzo-Luaces L; DeRubeis RJ
Bipolar Disord; 2016 Nov; 18(7):563-570. PubMed ID: 27805299
[TBL] [Abstract][Full Text] [Related]
14. Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression.
Benedetti F; Riccaboni R; Locatelli C; Poletti S; Dallaspezia S; Colombo C
J Clin Psychiatry; 2014 Feb; 75(2):133-40. PubMed ID: 24345382
[TBL] [Abstract][Full Text] [Related]
15. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.
Rybakowski JK; Permoda-Osip A; Bartkowska-Sniatkowska A
Int J Psychiatry Clin Pract; 2017 Jun; 21(2):99-103. PubMed ID: 28271731
[TBL] [Abstract][Full Text] [Related]
16. Long-term lamotrigine plus lithium for bipolar disorder: One year outcome.
Ghaemi SN; Schrauwen E; Klugman J; Berv DA; Shirzadi AA; Pardo TB; Goodwin FK
J Psychiatr Pract; 2006 Sep; 12(5):300-5. PubMed ID: 16998417
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
Laino CH; Fonseca C; Sterin-Speziale N; Slobodianik N; Reinés A
Eur J Pharmacol; 2010 Dec; 648(1-3):117-26. PubMed ID: 20826148
[TBL] [Abstract][Full Text] [Related]
18. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
19. Personality traits as predictors for the outcome of lithium augmentation in treatment-resistant depression.
Takahashi M; Suzuki M; Muneoka K; Tsuruoka Y; Sato K; Shirayama Y
Psychiatry Res; 2014 Dec; 220(3):1144-6. PubMed ID: 25453642
[TBL] [Abstract][Full Text] [Related]
20. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression.
Hassan AK; Farmer KC; Brahm NC; Neas BR
Int J Clin Pharm; 2016 Apr; 38(2):429-37. PubMed ID: 26935957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
